1. Home
  2. NBRG vs SPRO Comparison

NBRG vs SPRO Comparison

Compare NBRG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBRG

Newbridge Acquisition Limited Class A Ordinary Share

SELL

Current Price

$10.16

Market Cap

76.5M

Sector

Finance

ML Signal

SELL

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBRG
SPRO
Founded
2021
2013
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.5M
67.0M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
NBRG
SPRO
Price
$10.16
$0.80
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $5.33
AVG Volume (30 Days)
4.4K
★ 333.8K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 111.81
EPS
★ N/A
N/A
Revenue
N/A
★ $66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 39.24
52 Week Low
$9.59
$0.81
52 Week High
$10.17
$3.08

Technical Indicators

Market Signals
Indicator
NBRG
SPRO
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NBRG
SPRO

About NBRG Newbridge Acquisition Limited Class A Ordinary Share

Newbridge Acquisition Ltd is a blank check company.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: